Excerpt

The December 4, 2007, workshop was moderated by Wylie Burke, chair of the Roundtable, and consisted of panel presentations in four areas: the process of translation of innovations, practical incentives and barriers to translation, translation of genomic technology at the clinical level, and opportunities and constraints for translation both within the United States and globally. A discussion period followed each panel. At the conclusion of the meeting Burke offered a summary of the day’s presentations. While various types of genomic innovation were discussed, a number of presentations focused primarily on genomic testing technologies.

Contents

• The National Academies
• Planning Committee on Diffusion and Use of Genomic Innovations in Health and Medicine
• Roundtable on Translating Genomic-Based Research for Health
• Board on Health Sciences Policy
• Reviewers
• 1. Introduction
• 2. Translation of Innovations
  • A BROAD PERSPECTIVE
  • UNDERSTANDING TYPES OF INNOVATION AND IMPLICATIONS FOR POLICY
  • LESSONS FOR GENOMICS FROM OTHER TECHNOLOGIES
  • DISCUSSION
• 3. Practical Incentives and Barriers to Translation
  • TRANSLATING MEDICAL INNOVATIONS WITH APPROPRIATE EVIDENCE
  • ASSESSING TECHNOLOGY FOR USE IN HEALTH AND MEDICINE
  • INTEGRATING GENETIC TECHNOLOGY INTO A HEALTH CARE SYSTEM
  • VIEW FROM THE TRENCHES: CHALLENGES AND OPPORTUNITIES IN PERSONALIZED MEDICINE
  • DISCUSSION
• 4. Translation of Genomic Technology at the Clinical Level
  • A PRIMARY-CARE PROVIDER VIEW OF TRANSLATING GENOMIC INNOVATION
  • INTRODUCING A GENOMIC INNOVATION TO CLINICAL PRACTICE
  • DISCUSSION
• 5. Opportunities and Constraints for Translation of Genomic Innovations
  • THE GLOBAL PERSPECTIVE
  • FINDING VALUE IN TRANSLATION OF GENOMIC-BASED RESEARCH
  • DISCUSSION
• 6. Concluding Remarks
  • GENERAL OBSERVATIONS
• References
• Appendixes
  • A Workshop Agenda
  • B Biographical Sketches of the Workshop Speakers

Lyla M Hernandez, Rapporteur.

This project was supported by contracts between the National Academy of Sciences and American College of Medical Genetics (Unnumbered contract); American College of Physicians (Unnumbered contract); American Medical Association (Unnumbered contract); AstraZeneca Pharmaceuticals, Inc. (Unnumbered contract); Blue Cross/Shield Association (Unnumbered contract); Centers for Disease Control and Prevention (CDC) (Contract No. 200-2005-13434); College of American Pathologists (Unnumbered contract); Department of Veterans Affairs (VA) (Contract No. V101(93) P-2238); Eli Lilly and Company (Contract No. LRL-0028-07); Food & Drug Administration (Contract No. 223012460); Genetic Alliance (Unnumbered contract); Genomics Health, Inc. (Unnumbered contract); GlaxoSmithKline, Inc. (Unnumbered contract); Health Systems Research, Inc. (Contract No. 07-H0116); National Human Genome Research Institute (Contract No. N01-OD-4-2139, TO#189); National Institute of Child Health and Human Development (Contract No. N01-OD-4-2139, TO#189); National Society of Genetic Counselors (Unnumbered contract); Secretary’s Advisory Committee on Genetics, Health and Society (Contract No. N01-OD-4-2139, TO#189); and United Health Care (Unnumbered contract). Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the organizations or agencies that provided support for the project.

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.

IOM (Institute of Medicine). 2008. Diffusion and use of genomic innovations in health and medicine: Workshop summary. Washington, DC: The National Academies Press.